Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax (APG-2575) Phase I Study in Hematologic Malignancies
NCT03537482Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Aug 2018
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of lisaftoclax in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), Lymphoplasmacytic Lymphoma (LPL) and 4 more, sponsored by Ascentage Pharma. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Aug 2018; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia (CLL)Lymphoplasmacytic Lymphoma (LPL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03537482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03537482.